Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors

Ruben A. Mesa, Robyn M. Scherber, Holly L. Geyer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are clonal stem cell-derived malignancies that include primary myelofibrosis, polycythemia vera and essential thrombocythemia and are characterized by dysregulated Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling. Clinical manifestations include splenomegaly, cytopenias and/or systemic inflammation. Patients have a heterogeneous symptom profile that includes fatigue, loss of appetite, pruritus and night sweats, which significantly impact quality of life (QoL) and lead to poor survival outcomes. With the introduction of JAK inhibitors, improvement in disease-related symptoms has emerged as a realistic expectation of therapy and an integral measure of clinical efficacy. The JAK1/JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis and is currently under clinical development for polycythemia vera. Ruxolitinib has demonstrated significant reductions in symptom burden, with consequent improvements in QoL measures. With the potential to improve QoL, recognition of the impact and burden of symptoms on patients with MPNs is critical.

Original languageEnglish (US)
Pages (from-to)1989-1999
Number of pages11
JournalLeukemia and Lymphoma
Volume56
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Janus Kinases
Polycythemia Vera
Primary Myelofibrosis
Quality of Life
Essential Thrombocythemia
Philadelphia Chromosome
Neoplasms
Sweat
Splenomegaly
Appetite
Pruritus
Transducers
Fatigue
Stem Cells
Inflammation
Survival
Therapeutics
INCB018424

Keywords

  • Essential thrombocythemia
  • Janus kinase
  • Myelofibrosis
  • Polycythemia vera
  • Quality of life
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. / Mesa, Ruben A.; Scherber, Robyn M.; Geyer, Holly L.

In: Leukemia and Lymphoma, Vol. 56, No. 7, 01.07.2015, p. 1989-1999.

Research output: Contribution to journalArticle

Mesa, Ruben A. ; Scherber, Robyn M. ; Geyer, Holly L. / Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 7. pp. 1989-1999.
@article{d15923d065ab4d3dbe1ba14faa420a2c,
title = "Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors",
abstract = "Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are clonal stem cell-derived malignancies that include primary myelofibrosis, polycythemia vera and essential thrombocythemia and are characterized by dysregulated Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling. Clinical manifestations include splenomegaly, cytopenias and/or systemic inflammation. Patients have a heterogeneous symptom profile that includes fatigue, loss of appetite, pruritus and night sweats, which significantly impact quality of life (QoL) and lead to poor survival outcomes. With the introduction of JAK inhibitors, improvement in disease-related symptoms has emerged as a realistic expectation of therapy and an integral measure of clinical efficacy. The JAK1/JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis and is currently under clinical development for polycythemia vera. Ruxolitinib has demonstrated significant reductions in symptom burden, with consequent improvements in QoL measures. With the potential to improve QoL, recognition of the impact and burden of symptoms on patients with MPNs is critical.",
keywords = "Essential thrombocythemia, Janus kinase, Myelofibrosis, Polycythemia vera, Quality of life, Ruxolitinib",
author = "Mesa, {Ruben A.} and Scherber, {Robyn M.} and Geyer, {Holly L.}",
year = "2015",
month = "7",
day = "1",
doi = "10.3109/10428194.2014.983098",
language = "English (US)",
volume = "56",
pages = "1989--1999",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors

AU - Mesa, Ruben A.

AU - Scherber, Robyn M.

AU - Geyer, Holly L.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are clonal stem cell-derived malignancies that include primary myelofibrosis, polycythemia vera and essential thrombocythemia and are characterized by dysregulated Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling. Clinical manifestations include splenomegaly, cytopenias and/or systemic inflammation. Patients have a heterogeneous symptom profile that includes fatigue, loss of appetite, pruritus and night sweats, which significantly impact quality of life (QoL) and lead to poor survival outcomes. With the introduction of JAK inhibitors, improvement in disease-related symptoms has emerged as a realistic expectation of therapy and an integral measure of clinical efficacy. The JAK1/JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis and is currently under clinical development for polycythemia vera. Ruxolitinib has demonstrated significant reductions in symptom burden, with consequent improvements in QoL measures. With the potential to improve QoL, recognition of the impact and burden of symptoms on patients with MPNs is critical.

AB - Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are clonal stem cell-derived malignancies that include primary myelofibrosis, polycythemia vera and essential thrombocythemia and are characterized by dysregulated Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling. Clinical manifestations include splenomegaly, cytopenias and/or systemic inflammation. Patients have a heterogeneous symptom profile that includes fatigue, loss of appetite, pruritus and night sweats, which significantly impact quality of life (QoL) and lead to poor survival outcomes. With the introduction of JAK inhibitors, improvement in disease-related symptoms has emerged as a realistic expectation of therapy and an integral measure of clinical efficacy. The JAK1/JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis and is currently under clinical development for polycythemia vera. Ruxolitinib has demonstrated significant reductions in symptom burden, with consequent improvements in QoL measures. With the potential to improve QoL, recognition of the impact and burden of symptoms on patients with MPNs is critical.

KW - Essential thrombocythemia

KW - Janus kinase

KW - Myelofibrosis

KW - Polycythemia vera

KW - Quality of life

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=84938118384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938118384&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.983098

DO - 10.3109/10428194.2014.983098

M3 - Article

C2 - 25644746

AN - SCOPUS:84938118384

VL - 56

SP - 1989

EP - 1999

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -